Delivery Order SPE2DB20D2104-SPE2DB22FT89X
- Not listed
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $12,948.36 firm-fixed-price delivery order contract is for the supply of RESTASIS 0.05% eye emulsion, a prescription medication used to treat dry eye disease. The contract has an ultimate completion date of October 23, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of RESTASIS 0.05% eye emulsion. The $34,149.58 firm-fixed-price contract has a completion date of May 24, 2024. No set-aside designation was used. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,292.46 firm fixed-price delivery order is for the procurement of RESTASIS 0.05% eye emulsion, a specialty ophthalmic medication. The contract has a performance period through May 15, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as...
- This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,803.61 firm fixed-price contract is for the supply of RESTASIS 0.05% eye emulsion. The contract has an ultimate completion date of January 3, 2025 and is not designated as a set-aside requirement. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $7,001.84 Firm Fixed Price delivery order is for the supply of RESTASIS 0.05% eye emulsion, a prescription ophthalmic medication, with a period of performance through May 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves as a primary...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,947.09 firm-fixed-price delivery order is for the supply of RESTASIS 0.05% eye emulsion, a prescription eye medication. The order is placed under an Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of RESTASIS 0.05% eye emulsion, a specialty medication, valued at $2,233.96. It is a firm fixed-price contract with a completion date of May 12, 2023. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,117.68 firm fixed-price delivery order is for the supply of RESTASIS 0.05% eye emulsion, a specialty ophthalmic medication. The contract has an ultimate completion date of December 30, 2024 and was awarded on December 27, 2024. It is not designated as a set-aside contract. AmerisourceBergen holds a significant...
- This is a Delivery Order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $4,141.74, is for the supply of RESTASIS 0.05% eye emulsion 30s, a specialty pharmaceutical product. The contract does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
- This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, valued at $7,733.01, is for a delivery order of RESTASIS 0.05% eye emulsion with an ultimate completion date of November 26, 2024. The contract is a firm fixed-price agreement with no set-aside designation. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB22FT89XDelivery Order
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $12,687.85 firm fixed-price contract is for the supply of RESTASIS 0.05% eye emulsion, a specialty ophthalmic medication, with a completion date of September 13, 2022. Amerisourcebergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate $750,000 IDC with the Department of Justice Federal Bureau of Investigation for similar medical products and prescription drugs. These IDCs enable efficient government procurement of essential pharmaceutical and medical supplies, serving the healthcare needs of military personnel, veterans, and other federal beneficiaries. This specific contract award was not designated with any set-aside requirements, indicating open competition. The delivery order supports the provision of critical eye care medication to federal medical facilities and healthcare programs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $12.7k | 9/12/22 |